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Carcinogenicity Bioassays of Vinyl
Chloride Monomer: A Model of Risk
Assessment on an Experimental Basis
by Cesare Maltoni,* Giuseppe Lefemine,* Adriano
Ciliberti,* Giuliano Cotti* and Donata Carretti*
Data are presented regarding the final results of the Bentivoglio (Bologna) project on
long-term carcinogenicity bioassays of vinyl chloride (VC).
The experimental project studied the effects ofthe monomer, administered by different routes,
concentrations and schedules of treatment, to animals (near 7000) of different species, strains,
sex and age. To our knowledge this is the largest experimental carcinogenicity study performed
on a single compound by a single institution.
The results indicate that VC is a multipotential carcinogen, affecting a variety of organs and
tissues. In the experimental conditions studied, the neoplastic effects ofthe monomer were also
detected at low doses. The experimental and biological factors greatly affect the neoplastic
response to VC. Long-term carcinogenicity bioassays are, at present, a unique tool for the
identification and quantification of environmental and occupational risks. Precise and highly
standardized experimental procedures are needed to obtain data for risk assessment.
Introduction
The present report deals with the presentation of
the final results of our project on the long-term
carcinogenicity bioassays ofvinyl chloride (VC) (BT
project).
To our knowledge this project is the most exten-
sive experimental carcinogenesis study ever per-
formed on one industrial compound by a single
institution.
Planning, Materials, Methods and
Performance of the Experiment
Planning
The experiments of the project were planned
(a) to test the carcinogenicity of the compound;
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(b) to obtain information on the site and type of
tumors; (c) to evaluate the possible effects of the
routes of administration, with particular regard to
the ones reproducing potential human exposure;
(d) to assess, in quantitative terms, the level of
risk. The planning ofthe experiments was aimed at
achieving these goals.
The compound was tested on animals ofdifferent
species, strain, sex and age (Table 1), since it is
known that these factors may modify the neoplastic
responsequalitativelyandquantitatively. Thechoice
of the animals was made with the intention of
having an integrated system of complementary
biological models which could express a range, as
wide as possible, of neoplastic responses.
VC was administered by different routes: intra-
peritoneal (IP) injection, subcutaneous (SC) injec-
tion, inhalation and ingestion (by stomach tube),
the latter two being the major routes of potential
human exposure.
The monomer was administered at different
concentrations: 14 by inhalation levels and 6 inges-
tion levels for various periods of time, by continu-
ous or intermittent treatment (Table 2).
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Species Strain Sex Age
Rat Sprague- M, F Adult (10-21 wk)
Dawley Newborn (1 day)
Embryo (12 days pregnancy)
Rat Wistar M Adult
Mouse Swiss M, F Adult
Hamster Golden M Adult
The plan ofthe project is presented in Tables 3-9.
Material
VC was supplied from the same source in all
cases, and it contained very low amounts ofimpuri-
ties (Table 10). The oil employed as a vehicle in the
ingestion and injection experiments was pure vir-
gin olive oil from Tuscany.
The animals (except for the golden hamsters)
were breeds which have beenroutinely employed in
our laboratory formany years. It should be pointed
out that, whatever their use, all the animals ofour
colony undergo periodic examination and complete
autopsy, giving us extensive information concern-
ing their pathology.
The chambers for inhalation exposure were built
basically of stainless steel and glass.
For the ingestion treatment glass syringes and
stainless steel needles with round tips were used.
To control the level ofexposure in the inhalation
experiments, an automatic gas chromatography
system was used.
Table 2. BT project on VC: routes, concentrations and schedules.
Route Concentration Schedule
Inhalation 30,000, 10,000, 6000, 2500, 500, 250, 200, 4 hr/day, 5 days/wk, 52 wk
150, 100, 50, 25, 10, 5, 1 ppm
10,000, 6000, 2500, 500, 250, 50 ppm 4 hr/day, 5 days/wk, 17 wk
10,000, 6000 ppm 4 hr/day, 5 days/wk, 5 wk
10,000, 6000 ppm 4 hr/day, 1 day/wk, 25 wk
10,000, 6000 ppm 1 hr/day, 4 days/wk, 25 wk
10,000, 6000 ppm 4 hr/day, 7 days
Ingestion 50, 16.65, 3.33, 1.0, 0.3, 0.03, mg/kg body weight 5 times/wk, 52 wk
IP injection 4.25 mg 4, 3, or 2 times at
2 month intervals
4.25 mg Once only
SC injection 4.25 mg 'Once only
Table 3. Plan of long-term experiments on the effects of exposure by inhalation for 1 year to different doses of VC on adult
Sprague-Dawley rats (basic experiments).
Treatment Animals
Expt. Age, No. per
no. Route VC dose Duration Species Strain weeks No. 9 No. d Total group
BT1 Inhalation 10,000, 6000, 2500, 500 4 hr/day, Rat Sprague- 13 240 240 480 60
250, 50 ppm 5 days./wk, - Dawle7:
Untreated controls 52 wk
Treated controls
VA, 2500 ppm
BT2 Inhalation 200, 150, 100 ppm 4 hr/day, 5 Rat Sprague- 13 280 265 545 120-185
Untreated controls days/wk, 52 wk Dawley
BT6 Inhalation 30,000 ppm 4 hr/day, 5 Rat Sprague- 17 30 30 60 60
days/wk, 52 wk Dawley
BT9 Inhalation 50 ppm 4 hr/day, 5 Rat Sprague- 11 200 200 400 100 (c)
Untreated controls days/wk, 52 wk Dawley 300 (t)
BT15 Inhalation 25, 10, 5, 1 ppm 4 hr/day, 5 Rat Sprague- 13 300 300 600 120
Untreated controls days/wk, 52 wk Dawley
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Treatment Animals
Expt. Age, No. per
no. Route VC dose Duration Species Strain weeks No. 9 No. d Total group
BT3 Inhalation 10,000, 6000, 2500, 4 hr/day, Rat Sprague- 12 262 288 550 60-190
500, 250, 50 ppm 5 days/wk, Dawley
Untreated controls 17 wk
BT10 Inhalation 10,000, 6000, ppm 4 hr/day, 5 days/ Rat Sprague- 11 420 420 840 120
Untreated controls wk, 5 wk; 4 hr/ Dawley
day, 1 day/wk, 25
wk; 1 hr/day, 4
days/wk, 25 wk
Table 5. Plan of long-term experiments on the effects of age on vinyl chloride carcinogenicity.
Treatment Animals
Expt. Age, No. per
no. Route VC dose Duration Species Strain weeks No. 9 No. d Total group
BT5 Transpla- 10,000, 6000 ppm 4 hr/day, 7 days Rat Sprague- 19 110 36 146 30-54
cental (from 12th to 18th Dawley (breed-
day of pregnancy) ers) 12
days (em-
bryos)
BT14 Inhalation 10,000, 6000 ppm 4 hr/day, 5 Rat Sprague- 1 day 45 44 89 43-46
days/wk, 5 wk Dawley
Table 6. Plan of long-term experiments on the effects of strain on vinyl chloride carcinogenicity.
Treatment Animals
Expt. Age, No. per
no. Route VC dose Duration Species Strain weeks No. 9 No. d Total group
BT7 Inhalation 10,000, 6000, 2500, 500, 4 hr/day, 5 Rat Wistar 11 0 220 220 30-40
250, 50 ppm days/wk, 52 wk
Untreated controls
BT17 Inhalation 1 ppm 4 hr/day, 5 Rat Wistar 13 0 250 250 120-130
Untreated controls days/wk, 52 wk
Table 7. Plan of long-term experiments on the effects of species on vinyl chloride carcinogenicity.
Treatment Animals
Expt. Age, No. per
no. Route VC dose Duration Species Strain weeks No. 9 No. d Total group
BT4 Inhalation 10,000, 6000, 2500, 4 hr/day, 5 Mouse Swiss 11 500, 250 260 510 60-150
250, 50 ppm days/wk,
Untreated controls 30 wk
BT8 Inhalation 10,000, 6000, 2500, 4 hr/day, 5 Hamster Golden 11 10 268 268 30-62
500, 250, 50 ppm days/wk,
Untreated controls 30 wk
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Treatment Animals
Expt. Age, No. per
no. Route VC dose Duration Species Strain weeks No. Y No. d Total group
BT11 Ingestion 50, 16.65, 3.33 mg/kg 5 times/wk, Rat Sprague- 13 160 160 320 80
body weight in olive oil 52 wk Dawley
Controls, olive oil
BT27 Ingestion 1, 0.3, 0.03 mg/kg body 5 times/wk, 52 wk Rat Sprague- 10 300 300 600 150
weight in olive oil or 59 wka Dawley
Controls, olive oil
aFor 10 animals of each of the three exposed and control groups the treatment was planned to last 104 weeks, but it had to be
stopped because of animal intolerance.
Table 9. Plan of long-term injection experiments on vinyl chloride carcinogenicity.
Treatment Animals
Expt. Age, No. per
no. Route VC dose Duration Species Strain weeks No. Y No. d Total group
BT12 IP in- 4.25 mg in 1.0 cc 4, 3, 2, or 1 Rat Sprague- 13 150 150 300 60
jection olive oil times; two month Dawley
Controls, 1.0 cc olive oil intervals
BT13 SC in- 4.25 mg in 1.0 cc 1 injection Rat Sprague- 21 80 70 150 75
jection olive oil Dawley
Controls, 1.0 cc olive oil
Table 10. Maximum level of impurities in the VC used.
Impurity Concn, ppm
H20 10
Acetic aldehyde 5
Acetylene 2
Allene 5
Butane 8
1,3-Butadiene 10
Chlorophene 10
Diacetylene 4
Vinyl acetylene 10
Propine 3
Methyl chloride 100
Methods and Procedures
For the experiment on VC, as well as for any
other long-term experimental bioassays performed
in our laboratory, the procedure has been always
the same highly standardized and controlled one. In
particular, the following points in our laboratory
standard procedures, should be emphasized.
Compounds. All shipments of VC used were
examined in order to determine whether they meet
the required standards.
Concentrations. The concentrations, particularly
when VC was given by inhalation, were controlled
by continuous gas chromatographic monitoring.
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Modalities of Treatment. Treatment was al-
ways performed by the same people. This is par-
ticularly important for gavage, since the animals
become accustomed to the same operator.
Control of the Animals. The conditions of the
animals was checked three times daily. Every two
weeks the animals were examined to detect any
gross changes.
Weight of the Animals. The animals were
weighed every two weeks during treatment and
every eight weeks after the end of treatment.
Duration ofthe Experiments. In the VC pro-
ject, as in any otherlong-term bioassays performed
in our laboratory, the animals were kept alive until
spontaneous death.
Autopsy. Full autopsy was performed on each
animal. All parts of the body were explored,
including the central nervous system. Specimens
for histology included the brain, Zymbal glands,
interscapular brown fat, salivary glands, tongue,
lungs, liver, kidneys, adrenals, spleen, pancreas,
stomach, intestine, bladder, uterus, gonads and
any other organ with pathological lesions.
Histology. Specimens were trimmed in the
standard way. Sections were routinely stained with
Haematoxylin-Eosin and, when necessary, with
special techniques.
HistopathologicalExamination. Allsideswere
screened by ajunior pathologist and then reviewed
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the lesions were used by all pathologists. classified and coded following our laboratory codes
Classification ofData. All the anatomical sites (Tables 11-13).
Table 11. Codes of organs considered (sequence).
Code Organ
1 Skin (epidermis and dermis)
2 Epidermal appendages
3 Zymbal glands
4 Subcutaneous tissues
5 Mammary glands
6 Parotid glands
7 Submaxillary glands
8 Nasal and paranasal cavities
9 Oral cavity
10 Tongue
11 Lung
12 Pleura and pleural cavity
13 Esophagus
14 Forestomach
15 Glandular stomach
16 Intestine
17 Liver
18 Pancreas
19 Peritoneum and peritoneal cavity
20 Kidneys
21 Pelves
22 Ureters
23 Bladder
24 Ovaries
25 Uterus
26 Seminal vesicles
27 Prostate
28 Testicles
29 Epididymis
30 Hypophysis
31 Thyroid
Code Organ
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
Adrenals
Cerebrum
Cerebellum
Spinal marrow
Peripheral nervous system: ganglia
Peripheral nervous system: nerves
Eyes
Harderian glands
Skeletal muscles (diaphragm not included)
Diaphragm
Bones
Articulations
Heart
Pericardium and pericardial cavity
Large vessels
Thymus
Spleen
Axillary and inguinal lymph nodes
Head-neck lymph nodes
Interthoracic and parathymic lymph nodes
Intrabdominal lymph nodes
Lymph nodes of other sites
Bone marrow
Soft tissues of support
Interscapular fat pad
Trachea
Ear
Female external sex organs
Male external sex organs
Odontogenic apparatus
Gall bladder
Table 12. Codes of macroscopic changes.
Code Change Code Change
1 No change
2 Alopecia
3 Keratosis
4 Degenerative pathosis
5 Ulceration
6 Hyperemia, edema and hemorrhage
7 Phlogosis (including of abscess)
8 Pulmonary hepatization
9 Pulmonary emphysema
10 Irregular surface
11 Granulations and plaques
12 Simple thickening
13 Thickening ofcapsule
14 Fibrosis
15 In toto reduction
16 Atrophy
17 In toto enlargement
18 Augmentation in consistency
19 Dilatation of organ with cavity
20 Protrusion ofeyeball
21 Simple cyst
22 Hemorrhagic cyst
23 Multiple simple cyst
24 Multiple hemorrhagic cyst
25 Polypoid formation
26 Papillomatous formation and horn
27 Solid nodule
28 Hemorrhagic nodule
29 Cystic mass
30 Solid mass
31 Solid necrotic mass
32 Hemorrhagic mass
33 Ossifying mass
34 Serous effusion
35 Fibrinous-purulent effusion
36 Hemorrhagic effusion
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Code Change Code Change
1 No changes
2 Mild regressive changes
3 Serious regressive changes
4 Necrosis
5 Ulcer
6 Amyloidosis
7 Hyalinosis
8 Colloid-cystic degeneration
9 Calcifications
10 Emphysema
11 Vascular changes (hyperemia, dilatation of sinusoids
and other vessels, edema and hemorrhage)
12 Hematic cyst
13 Organized fibrinous coagulum
14 Hemorrhagic effusion
15 Acute phlogistic changes (including abscess)
16 Chronic phlogistic changes (also reactive)
17 Particular granulomatous changes
18 Phlogistic effusion
19 Thickening of capsule
20 Thickening of submesothelial tissues
21 Fibrosis
22 Post necrotic fibrosis (comprehensive ofcirrhosis)
23 Fibrous thickening of vessels
24 Cystic ectasia ofblood vessels with fibrosis
25 Cystic ectasia of blood vessels with fibrosis and
hyperplasia ofperithelial cells
26 Cystic ectasia of blood vessels with fibrosis and
dysplasia ofperithelial cells
27 Cellular depletion and atrophy (with or without
fibrosis)
28 Simple cyst
29 Hemorrhagic cyst
30 Multiple simple cyst
31 Multiple hemorrhagic cyst
32 Dilatation of organs with cavity (including
hydronephrosis)
33 Hyperplasia and squamous metaplasia
34 Glandular simple and cystic hyperplasia
35 Diffused parenchymal hyperplasia
36 Nodular parenchymal hyperplasia
37 Cortical hyperplasia
38 Medullary hyperplasia
39 Hyperplasia of stroma
40 Reactive hyperplasia
41 Simple proliferation oflymphoreticular cells with
myelopoiesis
42 Proliferation of angioblastic cells
43 Fibroangioblastic proliferation
44 Proliferation oflipocytes
45 Proliferation of biliary ducts
46 Proliferation of renal tubules and/or of
nephroblastema
47 Adenomatous hyperplasia
48 Cholangiofibrosis
49 Dysplasia (comprehensive ofneoplastic parenchymal
nodule of liver)
50 Simple and cystic glandular dysplasia
51 Cortical dysplasia
52 Medullary dysplasia
53 Dysplasia of angioblastic cells
54 Papillomatosis
55 Acanthomatosis
56 Angiomatosis
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57 Fibroangiomatosis
58 Simple polyp
59 Polyp with cellular distypias
60 Papilloma
61 Fibropapilloma
62 Acanthoma
63 Trichoepithelioma
64 Simple adenoma
65 Muciparous adenoma
66 Colloid-cystic adenoma
67 Exocrine pancreas adenoma
68 Endocrine pancreas adenoma (Islet cell adenoma)
69 Chromophobe adenoma
70 Chromophilic adenoma
71 Cortical adenoma
72 Medullary adenoma
73 Cholangioma
74 Hepatocellular adenoma or hepatoma
75 Tumor of granulosa and of theca
76 Leydig cell tumor
77 Other epithelial benign tumors
78 Fibroma
79 Mixoma
80 Lipoma
81 Leiomyoma
82 Rhabdomyoma
83 Chondroma
84 Osteoma
85 Angioma
86 Fibroangioma
87 Ossifying angioma
88 Other benign tumors of connective tissue
89 Fibroadenoma
90 Adenomyoma
91 Benign tumors of nervous ganglia (ganglioneuroma)
and benign sympathetic tumors of adrenal medulla
92 Benign tumors of peripheral nerves (neurilemoma)
93 Carcinoma
94 Carcinoma with metastases
95 Basocellular carcinoma
96 Basocellular carcinoma with metastases
97 Squamocellular carcinoma
98 Squamocellular carcinoma with metastases
99 Transitional cell carcinoma
100 Transitional cell carcinoma with metastases
101 Adenocarcinoma
102 Adenocarcinoma with metastases
103 Biliary duct adenocarcinoma
104 Biliary duct adenocarcinoma with metastases
105 Hepatocellular carcinoma or hepatocarcinoma
106 Hepatocarcinoma with metastases
107 Exocrine pancreas adenocarcinoma
108 Exocrine pancreas adenocarcinoma with metastases
109 Cortical adenocarcinoma
110 Cortical adenocarcinoma with metastases
111 Pheochromoblastoma
112 Pheochromoblastoma with metastases
113 Nephroblastoma
114 Nephroblastoma with metastases
115 Seminoma
116 Seminoma with metastases
117 Melanoma
118 Melanoma with metastases
119 Other malignant epithelial tumors
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Code Change Code Change
120 Other malignant epithelial tumors with metastases 145 Carcinosarcoma
121 Mesothelioma 146 Carcinosarcoma with metastases
122 Mesothelioma with metastases 147 Neuroblastoma
123 Fibrosarcoma 148 Neuroblastoma with metastases
124 Fibrosarcoma with metastases 149 Glioma (astrocytoma, oligodendroglioma, microglioma)
125 Mixosarcoma 150 Ependymoma
126 Mixosarcoma with metastases 151 Meningioma
127 Liposarcoma 152 Malignant tumors ofnervous ganglia and malignant
128 Liposarcoma with metastases sympathetic tumors of adrenal medulla
129 Leiomyosarcoma 153 Malignant tumors of nervous ganglia and malignant
130 Leiomyosarcoma with metastases sympathetic tumors ofadrenal medulla with metastases
131 Rhabdomyosarcoma 154 Malignant tumors ofperipheral nerves (malignant
132 Rhabdomyosarcoma with metastases schwannoma)
133 Chondrosarcoma 155 Malignant tumors ofperipheral nerves (malignant
134 Chondrosarcoma with metastases schwannoma) with metastases
135 Osteosarcoma 156 Characteristic tumors of eyes
136 Osteosarcoma with metastases 157 Lymphoreticular neoplastic localizations
137 Angiosarcoma 158 Secondary localizations of tumors from other
138 Angiosarcoma with metastases anatomical districts
139 Ossifying angiosarcoma 159 Neoplastic effusions
140 Ossifying angiosarcoma with metastases 160 Odontoma
141 Angiopericytosarcoma 161 Chondromatosis
142 Angiopericytosarcoma with metastases 162 Histiocytosis and benign histiocytoma
143 Other malignant tumors of connective tissue 163 Mesothelial hyperplasia
144 Other malignant tumors of connective tissue
with metastases
For each animal an individual final card was
prepared, which included data on experimental
factors, survival, weight at 6, 12, 18 and 24months,
and any gross and microscopic lesions. Samples are
shown in Figures 1 and 2.
Presentation ofPathological Data. The results
ofall VC experiments, as well as those ofany other
experiment performed in our laboratory, will be
presented in the final report (now in press) with the
same types oftables, in the same sequence.
This type ofpresentation has been made possible
by the knowledge of the basic pathology of the
animal used, which enabled us to make an ap-
proximated census of the expected lesions.
Such a procedure permits a quick comparison
among the results of different experiments of the
same project and possibly ofthe results ofprojects
studying different compounds.
Interpretation of the Data. The data were
subjected to statistical analysis. Although statistical
analysis provides an extremely important tool for
interpretingthe meaning oftheresults oflong-term
bioassays, it should be stressed that there may be
smaller differences between exposed and control
groups which do not reach statistical significance,
while these differences could still have meaning
from an oncological point of view (particularly in
the case of tumors which are infrequent in the
animal colony).
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Therefore, the most important data should be
commented on both in the light of the statistical
analysis performed and from a biological point of
view.
The methodological protocol adopted meets the
requirements ofthe recent Good Laboratory Practice
Act.
Results
Part of these results, namely those dealing with
seven basic experiments on the effects oflong-term
exposure to a range of 14 doses by inhalation (from
30,000 to 1 ppm) and ofsix doses byingestion (from
50mgto0.03mg/kgbw), on Sprague-Dawley rates,
were presented previously (1, 2).
A report, for limited circulation, dealing with
part ofthe results has also appeared (3).
The results of the whole project, with detailed
tables, will appear in a monograph which will
encompass data on survival rate, body weight,
regressive and inflammatory changes, benign and
malignant tumors, neoplastic precursors, and the
most important proliferative changes.
With this report we are presenting only tables
summarizing the most outstanding results and
information, and what we do believe to be the
integrative documentation and strictly necessary
comments.
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Agent: Vinyl chloride XVIII, 1
Experiment No.: BT 6
Group No.: I No. animal: 10
Type ofexposure Inhalation I, 1
Concentration: 30,000 ppm II, 1
Treatment protocol: 4 hr/day, 5 days/ VI, 5
week, 52 weeks
Species: Rat X, 1
Strain: Sprague-Dawley XI, 1
Sex: Female XII, 1
Age at start ofexperiment (weeks): 17 XIII, 10
Total dose received:
Age at death (weeks): 85
Periodfrom start oftreatment (weeks): 68
Weight (g)
6 months: 247
12 months: 278
18 months: 290
24 months:
FIGURE 1. Sample treatment protocol card.
Tables 15-31 presented data on the incidence of
the tumors which have been considered as depen-
dent or possibly correlated to VC exposure, in 17
different experiments on the effects of VC in
different animal systems, by different routes, at
different doses and with various schedules of treat-
ment. Explanations of abbreviations used in the
tables are given in Table 14.
The possible leukemogenic effect ofVC in golden
hamsters is expressed both bythe slightincrease in
incidence but more by the decrease in latency time
(from 16 weeks in animals treated at 10,000 ppm to
36 weeks in control animals).
Examples ofthe most characteristic microscopic
features of these tumors were given in a previous
publication (4).
The data on dose-response relationship in long-
term treatment experiments, by inhalation and by
ingestion, in Sprague-Dawley rats, Wistar rats and
Swiss mice, with reference to the incidence oftotal
malignant and benign tumors, and the most impor-
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tant neoplasias observed, are shown in TIables
32-63.
The striking effect of the influence of scheduled
treatment is pointed out by the results shown in
Table 64.
Examples ofthe marked influence ofthe animals
used in determining the neoplastic response are
shown in Tables 65-67, which point out the effects
of species, strain and age.
Conclusions
VC-dependent tumors are identified on the basis
of one or more of the following parameters:
(a) sharply enhanced incidence; (b) rare or excep-
tional occurrence in the colony ofthe animal used;
(c) dose-response relationship; (d) association of
precursor lesions.
From the presented data the following conclu-
sions may be drawn.
(1) VC causes tumors in all the different animal
systems tested.
(2) VC is a multipotential carcinogen, since it
causes tumors of different types in different sites
(Table 68).
(3) Some types oftumors are observed in all the
animals studied, i.e., liver angiosarcoma, whereas
others are observed in only one animal system.
(4) The degree of evidence of correlation be-
tween VC treatment and the tumors considered as
VC-dependent varies from tumor to tumor.
(5) VC shows carinogenic effects both when
given by inhalation and ingestion and possibly by
injection.
(6) Both through inhalation and ingestion exper-
iments there is a clear-cut dose-response relation-
ship.
(7) The duration of treatment and schedule of
treatment greatly affects the neoplastic response.
(8) The neoplastic response, in qualitative and
quantitative terms, is greatly affected by the spe-
cies, the strain and the sex ofthe animals studied.
(9) Newborn animals appear to be extremely
responsive and easily develop liver tumors, both
hepatocarcinomas and angiosarcomas.
(10) VC produces carcinogenic effects on em-
bryos via the placenta.
(11) With the above criteria for identifying VC-
dependent tumors, VC shows carcinogenic effects
even at lowdoses, namelydownto 50ppm and less.
(12) The results of the seven basic experiments
studying the effects of doses of VC as given by
inhalation (BT1, 2, 6, 9, 15), and ingestion (BTi1,
27), have been subject to statistical analysis follow-
ingthe Fisherexactprobabilitytest (p
- 0.05). The
total cancer-bearing animals and the tumors
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Site
Subcutaneous tissues
Lung
Pleura and pleural cavity
Forestomach
Liver
Peritoneum and peritoneal cavity
Adrenals
Harderian glands
Intrathoracic and parathymic
lymph node
Microscopic changes:
Site
Subcutaneous tissues
Lung
Pleura and pleural cavity
Forestomach
Liver
Peritoneum and
peritoneal cavity
Adrenals
Harderian glands
Intrathoracic and parathymic
lymph node
Type
Hemorrhagic nodule
Hemorrhagic nodule
Hemorrhagic effusion
No changes
Hemorrhage
No changes
Hemorrhagic mass
No changes
In toto enlargement
Type
Fibroangioma
Secondary neoplastic localization
(liver angiosarcoma)
Secondary neoplastic localization
(liver angiosarcoma)
Papilloma
Hepatocarcinoma
Angiosarcoma with metastases
Secondary neoplastic localization
(liver angiosarcoma)
Cortical adenoma
Abscess
No changes
Side
Sn
Sn
Side
Sn
Sn
No. Code
1 4, 28, D1
11, 28, D12
12, 36
14, 1
17, 6
19, 1
1 32, 32, Cl, Dl
39, 1, C1
51, 17
No. Code
4, 86
11, 158
(17, 138)
12, 158
(17, 138)
14, 60
17, 105
17, 138
19, 158
(17, 138)
32, 71, Cl
39, 15, Cl
51, 1
FIGURE 2. Sample record ofmacroscopic and microscopic changes.
Table 14. Abbreviations used in tables.a
Abbreviation
T
Ca
Ep T
Pa
Ac
Ad
Ad t
MT
BT
LAS
LA
ELAS
ELA
Nephro-BL
Neuro-BL
A
At
Neop. nod.
Nod. hyp.
Dif. hyp.
+ +
Tumor
Carcinoma
Epithelioma
Papilloma
Acanthoma
Adenoma
Adenoma in malignant transformation
Malignant tumors (total ifnot otherwise specified)
Benign tumors (total if not otherwise specified)
Liver angiosarcoma
Liver angioma
Extra-liver angiosarcoma
Extra-liver angioma
Nephroblastoma
Neuroblastoma
Angioblastic hyperplasia in liver
Angioblastic dysplasia in liver
Neoplastic nodules of liver
Nodular hyperplasia of liver
Diffused hyperplasia of liver
Marked
Very marked
aThe incidence oftotal malignant and benign tumours is given
as the total number oftumors per 100 animals (one animal may
bear more than one malignant or benign tumor) on the basis of
the tumors observed among the animals alive, when the first
tumor was observed in the experiment.
The incidence of specific tumour is given, as percent of the
animals bearing the tumor considered, referred to the animals
alive when the first tumor was observed (in parentheses).
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significantly in excess in these experiments, in
relation to dose, are given in Tables 69 and 70.
The Fisherexactprobability test at 95% confidence
is, in relation to the above, not "sensitive" enough,
in our experimental conditions.
Biologically, in our opinion, the followingresults,
although not statistically significant according to
the test used, should be given proper attention.
Extrahepatic angiosarcomas ofdifferent sites are
observed at a very low incidence dose in untreated
Sprague-Dawley rats of our colony. Results of
experiments BT1 and particularly BT9, however,
strongly suggest a relationship between these tu-
mors and VC exposure. This relationship is sup-
ported by the excessive incidence of extrahepatic
vascular tumors in mice treated with VC (BT4).
Few cases of hepatomas have been observed in
treated groups, particularly in BT1. This tumor is
exceptionally rare in our colony of animals, and
none have been observed inthe control group ofthe
17 experiments. Moreover the relationship with
treatment is supported by the fact that a high
incidence of hepatomas has been observed in
Sprague-Dawley rats, following neonatal exposure
to a high dose for a short period (BT14).
Inview oftheirrareness ornonobservation inthe
colony of animal used, for the following tumors it
should be stressed that attention should be paid to
11Table 15. Experiment BT1.a
Animals with tumors, %
Tumors/100
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 81.7 23.3 11.7 - 5.0 5.0 1.7 8.3 11.7 26.7 5.0 - 5.0
10,000 ppm (7/60) (3/60) (3/60) (1/60) (5/60) (7/60) (16/60) (3/60) (3/60)
II 60.0 38.3 22.0 3.4 5.1 6.8 1.7 8.5 5.1 11.9 3.4 1.7 -
6000 ppm (13/59) (2/59) (3/59) (4/59) (1/59) (5/59) (3/59) (7/59) (2/59) (1/59)
III 63.3 20.0 21.7 - 5.0 3.3 3.3 10.0 6.7 3.3 1.7 - 3.3
2500 ppm (13/60) (3/60) (2/60) (2/60) (6/60) (4/60) (2/60) (1/60) (2/60)
IV 51.7 13.3 10.0 - 1.7 1.7 8.3 10.0 - 6.7 1.7 - 1.7
500 ppm (6/60) (1/60) (1/60) (5/60) (6/60) - (4/60) (1/60) (1/60)
V 30.0 25.0 5.1 1.7 3.4 - 1.7 8.5 - - 3.4 - 3.4
250 ppm (3/59) (1/59) (2/59) (1/59) (5/59) (2/59) (2/59)
VI 15.0 36.7 1.7 - 1.7 3.3 - 1.7 - - 1.7 1.7 3.3
50 ppm (1/60) (1/60) (2/60) (1/60) (1/60) (1/60) (2/60)
VII
No treatment 13.3 43.3 - - - 3.4 - - - - 1.7
(control) (2/58) (1/58)
aExposure by inhalation to VC in air at 10,000, 6000, 2500, 500, 250, and 50 ppm; 4 hr/day, 5 days/week, for 52 weeks.
Sprague-Dawley rats, M and F, 13 weeks old. Results after 135 weeks (end ofexperiment).
Table 16. Experiment BT2.a
Animals with tumors, %
Tumors/100
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 35.0 21.7 10.0 3.3 0.8 0.8 2.5 5.8 - 3.3 4.2 - 5.0
200 ppm (12/120) (4/120) (1/120) (1/120) (3/120) (7/120) (4/120) (5/120) (6/120)
II 35.0 25.0 5.0 - - 0.8 - 9.2 - 3.4 3.4 1.7 5.0
150 ppm (6/119) (1/119) (11/119) (4/119) (4/119) (2/119) (6/119)
III 21.7 27.5 0.8 0.8 - - - 8.3 - 0.8 0.8 3.3 3.3
100 ppm (1/120) (1/120) (10/120) (1/120) (1/120) (4/120) (4/120)
IV
No treatment 15.7 21.6 - - 1.1 - - - - 1.1 1.1 1.6 1.0
(control) (2/185) (2/185) (2/185) (3/185) (2/185)
aExposure by inhalation to VC in air at 200, 150, 100 ppm; 4 hr/day, 5 days/week, for 52 weeks. Sprague-Dawley rats, M and F, 13
weeks old. Results after 143 weeks (end ofexperiment).
Table 17. Experiment BT6.a
Animals with tumors, %
Tumors/100
animals Fore- Main-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 100.0 50.0 30.0 1.7 1.7 5.0 1.7 - 1.7 58.3 1.7 18.3 3.3
30,000 ppm (18/60) (1/60) (1/60) (3/60) (1/60) (1/60) (35/60) (1/60) (11/60) (2/60)
aExposure by inhalation to VC in air at 30,000 ppm; 4 hr/day, 5days/week, for 52 weeks. Sprague-Dawley rats, M and F, 17weeks
old. Results after 68 weeks (end of experiment).
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Animals with tumors, %
Tumors/100
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 44.3 41.7 4.8 2.7 3.1 3.7 - 0.3 - 3.1 1.0 0.4 21.7
50 ppm (14/294) (8/294) (9/294) (11/294) (1/294) (9/294) (3/294) (1/294) (62/294)
II
No treatment 23.0 24.0 - - - - - - - - - 1.0 10.2
(control) (1/98) (10/98)
aExposure by inhalation to VC in air at 50 ppm; 4 hr/day, 5 days/week, for 52 weeks. Sprague-Dawley rats, M and F, 13 weeks old.
Results after 142 weeks (end of experiment).
Table 19. Experiment BT15.a
Animals with tumors, %
Tumors/100
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 33.3 58.3 4.2 0.8 - 2.5 - 0.8 - 3.3 - - 15.0
25 ppm (5/120) (1/120) (3/120) (1/120) (4/120) (17/120)
II 31.7 53.3 0.8 - 1.7 2.5 - - - 1.7 - - 17.6
10 ppm (1/119) (2/119) (3/119) (2/119) (21/119)
III 35.8 55.0 - - - - - - - 0.8 0.8 - 18.5
5 ppm (1/119) (1/119) (22/119)
IV 22.5 44.2 - - - - - - - 0.8 0.8 - 12.7
1 ppm (1/118) (1/118) (15/118)
V
No treatment 23.3 37.5 - - - 0.8 - - - 1.7 - - 5.8
(control) (1/120) (2/120) (7/120)
aExposure by inhalation to VC in air at 25, 10, 5, 1 ppm; 4 hr/day, 5 days/week, for 52 weeks. Sprague-Dawley rats, M and F, 13
weeks old. Results after 147 weeks (end of experiment).
Table 20. Experiment BT3.a
Animals with tumors, %
Tumors/100
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 45.0 20.0 - - - 1.7 1.7 1.7 15.5 15.5 8.6 1.7 1.7
10,000 ppm (1/58) (1/58) (1/58) (9/58) (9/58) (5/58) (1/58) (1/58)
II 53.3 25.0 1.7 - - 3.3 1.7 1.7 20.0 15.0 8.3 3.3 1.7
6000 ppm (1/60) (2/60) (1/60) (1/60) (12/60) (9/60) (5/60) (2/60) (1/60)
III 41.7 35.0 1.7 - - - 3.3 3.3 8.3 11.7 3.3 - 6.7
2500 ppm (1/60) (2/60) (2/60) (5/60) (7/60) (2/60) (4/60)
IV 15.0 35.0 1.7 - - - - - - 1.7 - - 5.0
500 ppm (1/60) (1/60) (3/60)
V 21.7 25.0 - 1.7 - 1.7 - 10.2 - 1.7 - 5.1 1.7
250 ppm (1/59) (1/59) (6/59) (1/59) (3/59) (1/59)
VI 18.3 25.0 - 1.7 - 1.7 - 5.2 - - 1.7 - 1.7
50 ppm (1/58) (1/58) (3/58) (1/58) (1/58)
VII
No treatment 14.7 20.0 - - 0.5 - - - - 1.0 0.5 - 2.6
(control) (1/190) (2/190) (1/190) (5/190)
aExposure by inhalation to VC in air at 10,000, 6000, 2500, 500, 250, and 50 ppm; 4 hr/day, 5 days/week, for 17 weeks.
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Tumors/100 Animals with tumors, %
animals Fore- Man-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 33.3 41.7 0.8 - - 0.8 0.8 - - 7.6 - 2.5 11.0
10,000 ppm (1/118) (1/118) (1/118) (9/118) (3/118) (13/118)
II 30.0 45.0 - 0.8 - 1.7 - 0.8 0.8 7.5 - 1.7 10.8
6000 ppm (1/120) (2/120) (1/120) (1/120) (9/120) (2/120) (13/120)
III 35.8 45.0 0.8 1.7 - 0.8 - - - 7.6 2.5 2.5 13.4
10,000 ppm (1/119) (2/119) (1/119) (9/119) (3/119) (3/119) (16/119)
IV 30.8 39.2 2.5 - 1.7 - - - - 4.2 3.4 1.7 9.3
6000 ppm (3/118) (2/118) (5/118) (4/118) (2/118) (11/118)
V 41.7 45.0 0.8 1.7 - 0.8 - 0.8 0.8 6.7 0.8 0.8 16.8
10,000 ppm (1/119) (2/119) (1/119) (1/119) (1/119) (8/119) (1/119) (1/119) (20/119)
VI 33.3 50.8 0.8 1.7 0.8 - 1.7 0.8 - 7.5 - 0.8 10.0
6000 ppm (1/120) (2/120) (1/120) (2/120) (1/120) (9/120) (1/120) (12/120)
VII
No treatment 16.6 41.0 - - - 0.4 - - - - 0.9 2.2 7.5
(control) (1/227) (2/227) (5/227) (17/227)
aExposure by inhalation to VC in air at 10,000, 6000, ppm; 4 hr/day, 5 days/week, for 5 weeks (groups I and II) or 1 hr/day, 4
days/week, for 25weeks (groups III and IV) or4hr/day, onceweekly, for25 weeks (groups VandVI) (100hr). Sprague-Dawley rats,
M and F, 13 weeks old. Results after 154 weeks (end ofexperiment).
Table 22. Experiment BT5.a
Tumors/100 Animals with tumors, %
animals Fore- Main-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 6.7 36.7 - - - - - - - 3.3 - - -
10,000 ppm (1/30)
II 6.7 23.3 - - - - - - - - - - -
6000 ppm
III 29.6 22.2 - - - - - 5.9 - 9.8 - 2.0 2.0
10,000 ppm (3/51) (5/51) (1/51) (1/51)
IV 21.9 46.9 - - - 3.1 - - - 9.4 3.1 3.1 6.2
6000 ppm (1/32) (3/32) (1/32) (1/32) (2/32)
aExposure byinhalation to VC in air at 10,000, and 6000 ppm ofbreeders; 4 hr/dayfor 1 week (from 12th to 18th day ofpregnancy).
Sprague-Dawley rats, M and F, 19weeks old (breeders). Breeders (groups I and II) and offsprings (groups III and IV). Results after
143 weeks (end ofexperiment).
Table 23. Experiment BT14.a
Tumors/100 Animals with tumors, %
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I
10,000 ppm 16.7 66.7 - - - - - - - - - - -
(breeders)
II
6000 ppm
- - - - - - -
(breeders)
III
10,000 ppm 100.0 55.5 34.1 - - 6.8 45.4 - - 2.3 2.3 -
(newborn) (15/44) (3/44) (20/44) (1/44) (1/44)
IV
6000 ppm 109.3 58.1 40.5 2.4 2.4 2.4 47.6 - - 4.8 4.8 - 2.4
(newborn) (17/42) (1/42) (1/42) (1/42) (20/42) (2/42) (2/42) (1/42)
aExposure by inhalation to VC in air at 10,000 and 6000 ppm, 4 hr/day, 5 days/week, for 5 weeks (from 1 day to 5 weeks ofage).
Sprague-Dawley rats, M and F, 21 weeks old (breeders) (groups I and II) and newborn (groups III and IV). Results after 124 weeks
(end ofexperiment).
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Tumors/100 Animals with tumors, %
animals Fore-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac
I 50.0 10.0 29.6 - - - - 3.7 11.1 7.4 - -
10,000 ppm (8/27) (1/27) (3/27) (2/27)
II 53.3 20.0 11.5 7.7 3.8 3.8 7.7 7.7 3.8 7.7 - -
6000 ppm (3/26) (2/26) (1/26) (1/26) (2/26) (2/26) (1/26) (2/26)
III 26.7 13.3 12.0 - 4.0 - 4.0 - 4.0 - 4.0 -
2500 ppm (3/25) (1/25) (1/25) (1/25) (1/25)
IV 30.0 10.0 10.7 3.6 - - - 7.1 - - - -
500 ppm (3/28) (1/28) (2/28)
V 13.3 16.7 3.7 - 3.7 3.7 - - - - 3.7 -
250 ppm (1/27) (1/27) (1/27) (1/27)
VI 16.7 6.7 - - - - - 3.6 - - - -
50 ppm (1/28)
VII
No treatment 15.0 15.0 - - 2.6 -
(control) (1/38)
aExposure byinhalation toVC in airat 10,000, 6000, 2500, 500, 250, and 50ppm; 4hr/day, 5days/week, for52weeks. Wistarrats, M,
11 weeks old. Results after 165 weeks (end of experiment).
Table 25. Experiment BT17.a
Tumors/100 Animals with tumors, %
animals Fore-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac
I 24.2 29.2 - 1.0 3.0 5.0 1.0 - - 2.0 - -
1 ppm (1/99) (3/99) (5/99) (1/99) (2/99)
II
No treatment 20.0 18.5 - - - - - - - 3.2 - 1.1
(control) (3/94) (1/94)
aExposure by inhalation to VC in air at 1 ppm; 4 hr/day, 5 days/week, for 52 weeks. Wistar rats, M, 13 weeks old. Results after 134
weeks (end of experiment).
Table 26. Experiment BT4.a
Animals with tumors, %
Tumors/100 animals Fore-
Group and Mammary Skin stomach
concentration MT BT LAS LA ELAS ELA Lung T Ca EpT Pa&Ac
I 50.0 98.3 17.8 10.7 1.8 7.1 82.1 23.2 7.1 1.8
10,000 ppm (10/56) (6/56) (1/56) (4/56) (46/56) (13/56) (4/56) (1/56)
II 56.7 100.0 21.7 11.7 1.7 5.0 78.3 13.3 11.7 1.7
6000 ppm (13/60) (7/60) (1/60) (3/60) (47/60) (8/60) (7/60) (1/60)
III 58.3 90.0 27.1 8.5 13.5 1.7 67.8 13.5 6.8 1.7
2500 ppm (16/59) (5/59) (8/59) (1/59) (40/59) (8/59) (4/59) (1/59)
IV 58.3 103.3 23.3 8.3 11.7 5.0 83.3 13.3 3.3 -
500 ppm (14/60) (5/60) (7/60) (3/60) (50/60) (8/60) (2/60)
V 63.3 98.3 30.0 18.3 5.0 5.0 68.3 20.0 1.7 1.7
250 ppm (18/60) (11/60) (3/60) (3/60) (41/60) (12/60) (1/60) (1/60)
VI 28.3 23.3 1.7 1.7 1.7 8.3 10.0 20.0 - 1.7
50 ppm (1/60) (1/60) (1/60) (5/60) (6/60) (12/60) - (1/60)
VII
No treatment 14.7 14.7 - - 0.7 0.7 10.0 0.7 1.3
(control) (1/150) (1/150) (15/150) (1/150) (2/150)
aExposure byinhalation to VC in air at 10,000, 6000, 2500, 500, 250, and 50 ppm; 4 hr/day, 5days/week, for 30weeks. Swissmice, M
and F, 11 weeks old. Results after 81 weeks (end of experiment).
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Tumors/100 Animals with tumors, %
animals Acoustic Fore-
Group and Hepa- Cholan- Cholan- Duct Skin Mela- stomachLeukae-
concentration MT BT LAS LA ELA tomas gio-Ca giomas EpT EpT nomas Pa&Ac miasb
I 50.0 73.3 - 3.3 6.7 - 6.7 13.3 3.3 23.3 3.3 33.3 16.7
10,000 ppm (1/30) (2/30) (2/30) (4/30) (1/30) (7/30) (1/30) (10/30) (5/30)
II 40.0 63.3 3.3 3.3 - 3.3 6.7 16.7 6.7 3.3 6.7 33.3 20.0
6000 ppm (1/30) (1/30) (1/30) (2/30) (5/30) (2/30) (1/30) (2/30) (10/30) (6/30)
III 43.3 103.3 - 6.7 - - - 26.7 3.3 10.0 3.3 56.7 30.0
2500 ppm (2/30) (8/30) (1/30) (3/30) (1/30) (17/30) (9/30)
IV 53.3 63.3 6.7 - 3.3 - - 20.0 10.0 23.3 - 30.0 16.7
500 ppm (2/30) (1/30) (6/30) (3/30) (7/30) - (9/30) (5/30)
V 30.0 43.3 - - 3.3 - - 20.0 - 10.0 3.3 13.3 20.0
250 ppm (1/30) (6/30) (3/30) (1/30) (4/30) (6/30)
VI 50.0 40.0 - - - - - 23.3 - 30.0 3.3 10.0 20.0
50 ppm (7/30) (9/30) (1/30) (3/30) (6/30)
VII
No treatment 20.0 46.7 - - - - - 36.7 - 5.0 - 5.0 13.3
(control) (22/60) (3/60) (3/60) (8/60)
aExposure by inhalation to VC in air at 10,000, 6000, 2500, 500, 250, and 50 ppm; 4 hr/day, 5 days/week, for 30 weeks. Golden
hamsters, M, 11 weeks old. Results after 109 weeks (end of experiment).
bLatency time in weeks: Group I, 16.7; Group II, 27.2; Group III, 30.8; Group IV, 19.0; Group V, 22.5; Group VI, 35.3; Group VII,
36.5.
Table 28. Experiment BT11.a
Tumors/100 Animals with tumors, %
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 38.7 35.0 21.2 3.7 2.5 2.5 - 2.5 - 1.2 1.2 2.5 5.0
50.00 mg/kg (17/80) (3/80) (2/80) (2/80) (2/80) (1/80) (1/80) (2/80) (4/80)
II 30.0 17.5 12.5 - - - - 3.7 - 2.5 - 1.2 7.5
16.65 mg/kg (10/80) (3/80) (2/80) (1/80) (6/80)
III 10.0 25.0 - - 2.5 1.2 - - - - - - 3.7
3.33 mg/kg (2/80) (1/80) (3/80)
IV
Olive oil 13.7 22.5 - - - - - - - 1.2 1.2 - 5.0
(control) (1/80) (1/80) (4/80)
aExposure byingestion (stomach tube) ofVCinolive oilat50.00, 16.65 and3.33mg/kgbodyweight, once daily, 4-5 days/week, for52
weeks. Sprague-Dawley rats, M and F, 13 weeks old. Results after 136 weeks (end of experiment).
Table 29. Experiment BT27.a
Tumors/100 Animals with tumors, %
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
concentration MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 24.7 35.3 2.0 - 0.7 - 0.7 - - 3.3 - 2.0 8.0
1.0 mg/kg (3/149) (1/149) (1/149) (5/149) (3/149) (12/149)
II 13.3 28.0 0.7 0.7 - - 0.7 - - - 0.7 1.3 2.7
0.3 mg/kg (1/148) (1/148) (1/148) (1/148) (2/148) (4/148)
III 18.0 31.3 - - - - - - - - 0.7 0.7 9.3
0.03 mg/kg (1/150) (1/150) (14/150)
IV
Olive oil 16.0 28.7 - - - - - - - 0.7 - 1.3 4.7
(control) (1/150) (2/150) (7/150)
aExposure byingestion (stomachtube)ofVC inolive oil at 1.0, 0.3, 0.03mg/kgbodyweight, oncedaily, 4-5 days/week, for59weeks.
Sprague-Dawley rats, M and F, 10 weeks old. Results after 136 weeks (end ofexperiment).
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Tumors/100 Animals with tumors, %
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
dose MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 13.8 25.0 - - - - - - - - - 1.8 1.8
4.25 mgx4 (1/56) (1/56)
II 16.7 28.3 - - 1.9 - - - - - - 1.9 1.9
4.25 mgx3 (1/53) (1/53) (1/53)
III 11.7 18.3 - - 1.8 - - - - - 1.8 - 5.3
4.25 mgx2 (1/56) (1/56) (3/56)
IV 20.0 35.0 - - - 1.8 - - - 1.8 - 3.6 3.6
4.25 mgx 1 (1/55) (1/55) (2/55) (2/55)
V
Olive oil 8.3 31.7 - - - - - - - - - 3.6
(control) (2/55)
aExposure by intraperitoneal injection of VC, 4.25 mg in olive oil (1 ml), 4, 3, 2 times, at two month intervals or once only.
Sprague-Dawley rats, M and F, 17 weeks old. Results after 144 weeks (end ofexperiment).
Table 31. Experiment BT13.a
Tumors/100 Animals with tumors, %
animals Fore- Mam-
Group and Hepa- Nephro- Neuro- Zymbal Skin stomach mary
dose MT BT LAS LA ELAS ELA tomas BL BL Gl.Ca EpT Pa&Ac MT
I 16.0 17.3 - 1.3 - - - - 4.0
4.25 mg (1/75) (3/75)
II
Olive oil 13.3 26.7 - - - 1.3 - - - 1.3 - - 1.3
(control) (1/75) (1/75) (1/75)
aExposure by subcutaneous injection ofVC, 4.25 mg, inolive oil (1 ml), single dose. Sprague-Dawley rats, M and F, 21 weeks old.
Results after 145 weeks (end of experiment).
Table 32. Incidence oftotal MT and BT in Sprague-Dawley rats, in relation to concentration ofVC administered by inhalation
for 52 weeks.
Tumors/100 animals
MT BT
Experiments Concentration (ppm) M F Total M F Total
BT 6 30,000 76.7 123.3 100.0 40.0 60.0 50.0
BT 1 10,000 80.0 83.3 81.7 26.7 20.0 23.3
6,000 46.7 73.3 60.0 13.3 63.3 38.3
2,500 53.3 73.3 63.3 16.7 23.3 20.0
500 23.3 80.0 51.7 13.3 13.3 13.3
250 23.3 36.7 30.0 23.3 26.7 25.0
BT 2 200 40.0 30.0 35.0 10.0 33.3 21.7
150 21.7 48.3 35.0 21.7 28.3 25.0
100 23.3 20.0 21.7 20.0 35.0 27.5
BT 1 50 6.7 23.3 15.0 23.3 50.0 36.7
BT 9 50 20.7 68.0 44.3 23.3 60.0 41.7
BT 15 25 20.0 46.7 33.3 31.7 85.0 58.3
10 18.3 45.0 31.7 30.0 76.7 53.3
5 25.0 46.7 35.8 28.3 81.7 55.0
1 15.0 30.0 22.5 18.3 70.0 44.2
Controls
BT 1 0 - 26.7 13.3 23.3 63.3 43.3
BT 2 0 15.3 16.0 15.7 21.2 22.0 21.6
BT 9 0 16.0 30.0 23.0 4.0 44.0 24.0
BT 15 0 18.3 28.3 23.3 20.0 55.0 37.5
17 October 1981Table 33. Incidence of LAS, LA, A+ +/+ + + T and A+ +/+ + + in Sprague-Dawley rats in relation to concentration of
VC administered by inhalation for 52 weeks.
Animals with tumors and correlated changes, %
LAS LA A++/+++ t A++/+++
Experiments Concentration, ppm M F Total M F Total M F Total M F Total
BT 6 30,000 16.6 43.3 30.0 - 3.3 1.7 6.7 6.7 6.7 6.7 13.3 10.0
BT 1 10,000 10.0 13.3 11.7 - - - - 3.3 1.7 3.3 6.7 5.0
6,000 10.3 33.3 22.0 - 6.7 3.4 - - - 20.0 16.7 18.3
2,500 20.0 23.3 21.7 - - - - - - 13.3 13.3 13.3
500 - 20.0 10.0 - - - 3.3 - 1.7 13.3 6.7 10.0
250 3.4 6.7 5.1 - 3.3 1.7 - - - 20.0 10.0 15.0
BT 2 200 11.7 8.3 10.0 3.3 3.3 3.3 6.6 5.0 5.8 18.3 10.0 14.1
150 1.7 8.3 5.0 - - - 8.3 10.0 9.2 18.3 6.6 12.5
100 - 1.7 0.8 1.7 - 0.8 1.7 6.6 4.2 8.3 5.0 6.6
BT 1, BT 9 50 1.1 7.2 4.2 1.1 3.3 2.2 1.7 1.1 1.4 5.5 15.5 10.5
BT 15 25 1.7 6.7 4.2 - 1.7 0.8 1.7 - 0.8 3.3 5.0 4.2
10 - 1.7 0.8 - - - 1.7 - 0.8 1.7 1.7 1.7
5 - - - _ _ _ _ _ _ _ _ _
1 - - - - _ _ _ _ _ _ _ _
Control 0 - - - - - - - - - - 2.5 1.3
BT 1, BT 2,
BT 9, BT 15
Table 34. Incidence of ELAS, and ELA in Sprague-Dawley rats in relation to concentration ofVC administered by inhalation
for 52 weeks.
Animals with tumors, %
ELAS ELA
Experiments Concentration, ppm M F Total M F Total
BT 6 30,000 - 3.3 1.7 3.3 6.7 5.0
BT 1 10,000 6.7 3.3 5.0 6.7 3.3 5.0
6,000 3.4 6.7 5.1 6.9 6.7 6.8
2,500 6.7 3.3 5.0 3.3 3.3 3.3
500 - 3.3 1.7 3.3 - 1.7
250 3.4 3.3 3.4 - - -
BT 2 200 1.7 - 0.8 - 1.7 0.8
150 - - - - 1.7 0.8
100 - - - - - -
BT 1, BT 9 50 2.3 3.3 2.8 4.6 2.8 3.7
BT 15 25 - - - 5.0 - 2.5
10 3.3 - 1.7 3.3 1.7 2.5
5 - - _ _ _ _
1 - _ _ _ _ _
Controls 0 0.9 - 0.4 0.4 0.8 0.6
BT 1, BT 2,
BT 9, BT 15
Table 35. Incidence ofhepatomas, neoplastic liver nodules, nodular hyperplasia ofthe liver and diffuse hyperplasia ofthe liver
in Sprague-Dawley rats in relation to concentration of VC administered by inhalation for 52 weeks.
Experiments
BT 6
BT 1
Animals with tumors and correlated changes, %
Hepatomas Neopl. nod. Nod. hyp. Diff. hyp.
Concentration, ppm M F Total M F Total M F Total M F Total
30,000
10,000
6,000
2,500
500
250
- 3.3 1.7 3.3 13.3 8.3 13.3 10.0 11.7 - - -
3.3 - 1.7 - - - 3.3 3.3 3.3 3.3 6.7 5.0
- 3.3 1.7 3.3 - 1.7 13.3 6.7 10.0 3.3 3.3 3.3
- 6.7 3.3 - 3.3 1.7 6.7 13.3 10.0 - 3.3 1.7
- 16.7 8.3 - - - - 10.0 5.0 13.3 6.7 10.0
3.3 - 1.7 - - - 23.3 - 11.7 3.3 - 1.7
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Animals with tumors and correlated changes, %
Hepatomas Neopl. nod. Nod. hyp. Diff. hyp.
Experiments Concentration, ppm M F Total M F Total M F Total M F Total
BT 2 200 1.7 3.3 2.5 3.3 1.7 2.5 20.0 13.3 16.7 38.3 18.3 28.3
150 - - - 1.7 - 0.8 8.3 13.3 10.8 16.7 25.3 20.8
100 - - - - - - 5.0 23.3 14.2 26.7 13.3 20.0
BT 1, BT 9 50 - - - 0.5 - 0.3 13.3 9.4 11.4 2.8 3.3 3.0
BT 15 25 - - - - - - 15.0 8.3 11.7 5.0 10.0 7.5
10 - - - - - - 20.0 5.0 12.5 10.0 6.7 8.3
5
- - - - - - 1.7
- 0.8 - - -
1 - - - - - - 3.3 - 1.7 1.7 - 0.8
Controls 0 - - - - 0.4 0.2 0.4 0.8 0.6 0.9 2.9 1.9
BT 1, BT 2,
BT 9, BT 15
Table 36. Incidence of nephroblastoma in Sprague-Dawley rats in relation to concentration of VC administered by inhalation
for 52 weeks.
Animals with NEPHRO-BL, %
Experiment Concentration, ppm M F Total
BT 6 30,000 _ _ _
BT 1 10,000 10.0 6.7 8.3
6,000 13.8 3.3 8.5
2,500 16.7 3.3 10.0
500 6.7 13.3 10.0
250 3.4 13.3 8.5
BT 2 200 8.3 3.3 5.8
150 13.3 5.0 9.2
100 13.3 3.3 8.3
BT 1, BT 9 50 - 1.1 0.6
BT 15 25 1.7 - 0.8
10 - _ _
5 _ _
1 _ _ _
Controls 0
BT 1, BT 2,
BT 9, BT 15
Table 37. Incidence ofneuroblastoma inSprague-Dawley rats in relation to concentration ofVC administered by inhalation for
52 weeks.
Animals with NEURO-BL, %
Experiments Concentration, ppm M F Total
BT 6 30,000 3.3 - 1.7
BT 1 10,000 6.7 16.7 11.7
6,000 6.9 3.3 5.1
2,500 6.7 6.7 6.7
500 _ _ _
250 - - -
BT 2 200 - - -
150 - - -
100 - - -
BT 1, BT 9 50 _ _ _
BT 15 25 - _ _
10
1 _ _ _
Controls 0
BT 1, BT 2, BT 9, BT 15
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19 October 1981Table 38. Incidence of zymbal gland carcinoma in Sprague-Dawley rats in relation to concentration of VC administered by
inhalation for 52 weeks.
Animals with Zymbal gland CA, %
Experiment Concentration, ppm M F Total
BT 6 30,000 56.6 60.0 58.3
BT 1 10,000 33.3 20.0 26.7
6,000 10.3 13.3 11.9
2,500 3.3 3.3 3.3
500 10.0 3.3 6.7
250 - - -
BT 2 200 5.0 1.7 3.3
150 - 6.7 3.4
100 - 1.7 0.8
BT 1, BT 9 50 2.3 2.8 2.5
BT 15 25 5.0 1.7 3.3
10 1.7 1.7 1.7
5 - 1.7 0.8
1 1.7 - 0.8
Controls 0 0.9 0.8 0.9
BT 1, BT 2, BT 9, BT 15
Table 39. Incidence of forestomach papilloma and acanthoma in Sprague-Dawley rats in relation to concentration of VC
administered by inhalation for 52 weeks.
Animals with forestomach Pa and Ac, %
Experiment Concentration, ppm M F Total
BT 6 30,000 16.7 20.0 18.3
BT 1 10,000 - - _
6,000 - 3.3 1.7
2,500 - - _
500 - - _
250 - - -
BT 2 200 - - -
150 3.3 - 1.7
100 3.3 3.3 3.3
BT 1, BT 9 50 1.1 - 0.6
BT 15 25 - -
10 - _
5 _ _
1 _ _
Controls 0 1.3 0.4 0.9
BT 1, BT 2, BT 9, BT 15
their onset, even at doses below the ones with
statistically significant results.
An excess of Zymbal gland carcinomas is ob-
served down to 50 and 25 ppm.
Liver angiosarcomas are extremely rare in the
colony used (4 cases over several thousand un-
treated animals). Therefore, one must consider the
onset of these tumors as important even at doses
not shown by statistical analysis, and particularly
below 50 ppm (5 liver angiosarcomas out of 120
animals at 25 ppm, and 1 liver angiosarcoma out of
20
120 animals at 10 ppm), and at 1 mg/kg (3 liver
angiosarcomas outof150animals), and at0.3mg/kg
(1 liver angiosarcoma out of 150 animals).
The onset of a few nephroblastomas observed
after inhalation treatment at doses below 100 ppm
and in groups treated by ingestion with 50 and
16.65 mg/kg, is not casual in our opinion, given the
extreme rarity ofthese tumors in rats.
Neuroblastomas have never been observed by
us, up to the present, in the Sprague-Dawley rats
used in our laboratory as control or otherwise
Environmental Health PerspectivesTable 40. Incidence ofmammary malignant tumor in female
Sprague-Dawley rats in relation to concentration of VC
administered by inhalation for 52 weeks.
Concentration, Animals with
Experiment ppm Mammary MT, %
BT6 30,000 6.7
BT 1 10,000 10.0
6,000 -
2,500 6.7
500 3.3
250 6.7
BT 2 200 8.3
150 10.0
100 6.7
BT 1 50 6.7
BT 9 50 40.7
BT 15 25 28.3
10 35.0
5 38.3
1 23.3
Controls
BT 1 0 -
BT2 0 2.0
BT9 0 18.0
BT 15 0 10.0
Table 41. Incidence oftotal MTand BT in male Wistarrats in
relation to concentration of VC administered by inhalation
for 52 weeks.
Tumors/100 Animals
Concentration,
Experiment ppm MT BT
BT 7 10,000 50.0 10.0
6,000 53.3 20.0
2,500 26.7 13.3
500 30.0 10.0
250 13.3 16.7
50 16.7 6.7
BT 17 1 24.2 29.2
Controls
BT 7 0 15.0 15.0
BT 17 0 20.0 18.5
Table 43. Incidence ofELAS and ELA in male Wistar rats in
relation to concentration of VC administered by inhalation
for 52 weeks.
Animals with tumors, %
Concentration,
Experiment ppm ELAS ELA
BT 7 10,000 - -
6,000 3.8 3.8
2,500 4.0 -
500 - _
250 3.7 3.7
50 - _
BT 17 1 3.0 5.0
Controls 0 0.7
BT 7, BT 17
treated. Therefore we consider as dependent on
treatment the onset ofthese tumors, even at doses
below 10,000 ppm, i.e., 6000 and 2500 ppm.
The meaningin oncological terms ofthe results at
the lowest doses may be better evaluated in consid-
ering, not singly, but together, the tumors found to
be VC-dependent (Table 71).
None (or no increase) of the specifically VC
related tumors shown in Table 71, observed in the
seven basic experiments, was found at doses of 5
and 1 ppm (by inhalation) and 0.03 mg/kg (by
ingestion).
General Comments
VC long-term experimental study led to the
discovery of VC carcinogenicity, and as a direct
consequence, to what probably has been the great-
est effort ever made at controlling the exposure to
an industrial carcinogen in the workplace (Table
72).
Moreover, long-term carcinogenicity bioassays
on VC are a crucial step in the field ofenvironmen-
tal and occupational carcinogenesis which, in turn,
Table 42. Incidence of LAS, LA, A+ +/+ + + T and A+ +/+ + + in male Wistar rats in relation to concentration of
VC administered by inhalation for 52 weeks.
Animals with tumors and correlated changes, %
Experiment Concentration, ppm LAS LA A+ +/+++++ A+ +/+ + +
BT 7 10,000 29.6 - 3.3 -
6,000 11.5 7.7 - 3.3
2,500 12.0 - 3.3 -
500 10.7 3.6 3.3 3.3
250 3.7 - 3.3 -
50 - - - -
BT 17 1 - 1.0 1.7 0.8
Controls 0 - - -
BT 7, BT 17
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October 1981 21Table 44. Incidence ofhepatomas, neoplastic liver nodules, nodular hyperplasia ofthe liver and diffuse hyperplasia ofthe liver
in male Wistar rats in relation to concentration of VC administered by inhalation for 52 weeks.
Animals with tumors and correlated changes, %
Experiment Concentration, ppm Hepatomas Neop.nod. Nod.hyp. Dif.hyp.
BT 7 10,000 - - 6.7 -
6,000 7.7 6.7 3.3 6.7
2,500 4.0 - 6.7 6.7
500 - 6.7 - 3.3
250 - - - 16.7
50 - - - 10.0
BT 17 1 1.0 - 5.0 4.2
Controls 0 - - 1.2 2.3
BT 7, BT 17
Table 45. Incidence of NEPHRO-BL in male Wistar rats in
relation to concentration of VC administered by inhalation
for 52 weeks.
Concentration, Animals with
Experiment ppm NEPHRO-BL, %
BT 7 10,000 3.7
6,000 7.7
2,500 -
500 7.1
250 -
50 3.6
BT 17 1 -
Controls 0
BT 7, BT 17
Table 46. Incidence of NEURO-BL in male Wistar rats in
relation to concentration of VC administered by inhalation
for 52 weeks.
Concentration, Animals with
Experiment ppm NEURO-BL, %
BT 7 10,000 11.1
6,000 3.8
2,500 4.0
500 -
250 -
50 -
BT 17 1 -
Controls 0 -
BT 7, BT 17
are among the most important areas of public
health nowadays.
These studies have demonstrated that long-term
carcinogenicity bioassays: may predict carcinogenic
risk for humans; may give indication ofthe level of
risk, inrelation to dose; mayprovide information on
22
Table 47. Incidence of Zymbal gland CA in male Wistar rats
inrelation to concentration ofVC administered by inhalation
for 52 weeks.
Concentration, Animals with
Experiment ppm Zymbal gland CA, %
BT 7 10,000 7.4
6,000 7.7
2,500 -
500 -
250 -
50 -
BT 17 1 2.0
Controls 0 2.3
BT 7, BT 17
Table 48. Incidence offorestomach Pa and Ac in male Wistar
rats in relation to concentration of VC administered by
inhalation for 52 weeks.
Animals with
Concentration, forestomach Pa
Experiment ppm and Ac, %
BT 7 10,000 -
6,000 -
2,500 -
500 -
250 -
50 -
BT 17 1 -
Controls 0 0.7
BT 7, BT 17
possible target organs and, in general terms, on the
quality ofneoplastic response; may represent a tool
for obtaininginformation on the relative risk repre-
sented by different compounds, provided that they
are tested under the same standard conditions
(Table 73); have revealed the need to identify
Environmental Health PerspectivesTable 49. Incidence of total MT and BT in Swiss mice in relation to concentration of VC administered by inhalation for 30
weeks.
Tumors/100 animals
MT BT
Experiment Concentration, ppm M F Total M F Total
BT 4 10,000 16.6 83.3 50.0 83.3 113.3 98.3
6,000 26.7 86.6 56.7 100.0 100.0 100.0
2,500 40.0 76.7 58.3 80.0 100.0 90.0
500 36.7 80.0 58.3 93.3 113.3 103.3
250 36.7 90.0 63.3 116.7 80.0 98.3
50 6.7 50.0 28.3 20.0 26.7 23.3
0 6.2 24.3 14.7 13.7 15.7 14.7
Table 50. Incidence ofLAS and LA in Swiss mice in relation to concentration ofVC administered by inhalation for 30 weeks.
Animals with tumors, %
LAS LA
Experiment Concentration, ppm M F Total M F Total
BT 4 10,000 3.8 30.0 17.8 3.8 16.7 10.7
6,000 6.7 36.7 21.7 6.7 16.7 11.7
2,500 20.7 33.3 27.1 6.9 10.0 8.5
500 20.0 26.7 23.3 3.3 13.3 8.3
250 30.0 30.0 30.0 20.0 16.7 18.3
50 3.3 - 1.7 - 3.3 1.7
0 - _ - _ _ _
Table 51. Incidence ofELAS and ELA in Swiss mice in relation to concentration ofVC administered by inhalation for30weeks.
Animals with tumors, %
ELAS ELA
Experiment Concentration, ppm M F Total M F Total
BT 4 10,000 - 3.3 1.8 7.7 6.7 7.1
6,000 - 3.3 1.7 6.7 3.3 5.0
2,500 13.8 13.3 13.5 - 3.3 1.7
500 6.7 16.7 11.7 3.3 6.7 5.0
250 6.7 3.3 5.0 6.7 3.3 5.0
50 3.3 - 1.7 3.3 13.3 8.3
0 - 1.4 0.7 1.2 - 0.7
Table52. Incidence oflungtumors (AdandAd t ) inSwissmice inrelationtoconcentration ofVC administeredby inhalationfor
30 weeks.
Animals with lung tumors (Ad and Ad T), %
Experiment Concentration, ppm M F Total
BT 4 10,000 76.9 86.7 82.1
6,000 76.7 80.0 78.3
2,500 62.1 73.3 67.8
500 80.0 86.7 83.3
250 80.0 56.7 68.3
50 10.0 10.0 10.0
0 10.0 10.0 10.0
23 October 1981Table 53. Incidence ofmammary CA in female Swiss mice in
relation to concentration of VC administered by inhalation
for 30 weeks.
Animals with
Experiment Concentration, ppm mammary CA, %
BT 4 10,000 43.3
6,000 26.7
2,500 26.7
500 23.3
250 40.0
50 40.0
0 1.4
animal systems more equivalent to humans in
neoplastic response, which in turn depends on
partly-known factors, such as basic "spontaneous"
tumorigram and enzymatic profiles.
Prospects
At present the most important goal of research
on environmental and occupational carcinogenesis
is, in our own view, the extrapolation of results
Table 54. Incidence offorestomach Paand Cain Swiss mice in relation to concentration ofVC administered by inhalation for30
weeks.
Animals with forestomach Pa and Ac, %
Experiment Concentration, ppm M F Total
BT 4 10,000 - 3.3 1.8
6,000 3.3 - 1.7
2,500 - 3.3 1.7
500 - - -
250 3.3 1.7
50 3.3 1.7
0 -
Table 55. Incidence oftotal MT and BT in Sprague-Dawley rats in relation to concentration ofVC administered by ingestionfor
52 (or 59) weeks.
Tumors/100 animals
MT BT
Experiment Concentration, mg/kg M F Total M F Total
BT 11 50.00 35.0 42.5 38.7 20.0 50.0 35.0
16.65 22.5 37.5 30.0 - 35.0 17.5
3.33 5.0 15.0 10.0 2.5 47.5 25.0
BT 27 1.0 13.3 36.0 24.7 12.0 58.7 35.3
0.3 12.0 14.7 13.3 20.0 36.0 28.0
0.03 8.0 28.0 18.0 14.7 48.0 31.3
Controls
BT 11 0 12.5 15.0 13.7 10.0 35.0 22.5
BT 27 0 8.0 24.0 16.0 9.3 48.0 28.7
Table 56. Incidence of LAS, LA, A+ +/+ + + T and A+ +/+ + + in Sprague-Dawley rats in relation to concentration of
VC administered by ingestion for 52 (or 59) weeks.
Animals with tumors and correlated changes, %
LAS LA A++/+++ t A++/+++
Experiment Concentration, mg/kg M F Total M F Total M F Total M F Total
BT 11 50.00 20.0 22.5 21.2 2.5 5.0 3.7 7.5 5.0 12.5 7.5 10.0 8.7
16.65 10.0 15.0 12.5 - - - 5.0 5.0 5.0 7.5 15.0 11.2
3.33 - - - - - - 2.5 7.5 5.0 15.0 22.5 18.7
BT27 1.0 1.3 2.7 2.0 - - - - - - 1.3 6.7 4.0
0.3 - 1.4 0.7 - 1.4 0.7 - 1.3 0.7 1.3 1.3 1.3
0.03 - - - _-
- - - - - -
Controls 0 - - - - _ _ - 0.9 0.4 - 0.9 0.4
BT 11, BT 27
24 Environmental Health PerspectivesTable 57. Incidence ofELAS and ELA in Sprague-Dawley rats in relation to concentration ofVC administered by ingestion for
52 (or 59) weeks.
Animals with tumors, %
ELAS ELA
Experiment Concentration, mg/kg M F Total M F Total
BT 11 50.00 - 5.0 2.5 2.5 2.5 2.5
16.65 - - - - - -
3.33 - 5.0 2.5 - 2.5 1.2
BT 27 1.0 - 1.3 0.7 - -
0.3 - _ _ _
0.03 - _ _ _ _ _
Controls 0 -
BT 11, BT 27
Table 58. Incidence ofhepatomas, neoplastic liver nodules, nodular hyperplasia ofthe liver, and diffuse hyperplasia ofthe liver
in Sprague-Dawley rats in relation to concentration of VC administered by ingestion for 52 (or 59) weeks.
Animals with tumors and correlated changes, %
Hepatomas Neop.nod. Nod.hyp. Dif.hyp.
Experiment Concentration, mg/kg M F Total M F Total M F Total M F Total
BT 11 50.00 - - - - 5.0 2.5 17.5 17.5 17.5 15.0 15.0 15.0
16.65 - - - - - - 17.5 30.0 23.7 25.0 32.5 28.7
3.33 - - - 2.5 - 1.2 10.0 20.0 15.0 15.0 42.5 28.7
BT 27 1.0 1.3 - 0.7 1.3 2.7 2.0 6.7 13.3 10.0 6.7 14.7 10.7
0.3 1.3 - 0.7 - 1.3 0.7 9.3 6.7 8.0 - 10.7 5.3
0.03 - - - - - - 4.0 6.7 5.3 - 10.7 5.3
Controls 0 - - - - 0.9 0.4 5.2 6.1 5.6 7.0 8.7 7.8
BT 11, BT 27
Table 59. Incidence ofNEPHRO-BL in Sprague-Dawley rats
in relation to concentration ofVC administered by ingestion
for 52 (or 59) weeks.
Animals with
NEPHRO-BL, %
Experiments Concentration, mg/kg M F Total
BT 11 50.00 2.5 2.5 2.5
16.65 5.0 2.5 3.7
3.33 - - -
BT 27 1.0 - - -
0.3 - - -
0.03 - - -
Controls 0 - - -
BT 11, BT 27
from animal to human, both in qualitative and in
quantitative terms.
VC carcinogenicity may again provide an impor-
tant tool towards solving this problem.
We now know a great deal about the effects of
VC in experimental animal systems, both in quali-
tative and quantitative terms.
Onthe otherhand, epidemiologicalinvestigations
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Table 60. Incidence ofNEURO-BL in Sprague-Dawley rats in
relation to concentration ofVC administered by ingestionfor
52 (or 59) weeks.
Animals with
NEURO-BL, %
Experiments Concentration, mg/kg M F Total
BT 11 50.00 - - -
16.65 - - -
3.33 - - -
BT 27 1.0 - - -
0.3 - - -
0.03 - - -
Controls 0 - - -
BT 11, BT 27
on occupationally exposed population groups have
been made and are being carried out in different
parts ofthe world, particularly in Western Europe
and in the U.S.A., with reference to general
pathology and neoplasias.
If these epidemiological investigations provide
precise figures on the whole group considered,
including figures on the level and length of expo-
25Table 61. Incidence of Zymbal gland CA in Sprague-Dawley
rats in relation to concentration of VC administered by
ingestion for 52 (or 59) weeks.
Animals with
Zymbal gland CA,
Experiments Concentration, mg/kg M F Total
BT 11 50.00 2.5 - 1.2
16.65 2.5 2.5 2.5
3.33 - - -
BT 27 1.0 2.7 4.0 3.3
0.3 - - -
0.03 - - -
Controls 0 - 1.7 0.9
BT 11, BT 27
Table 62. Incidence of forestomach Pa and Ac in Sprague-
Dawley rats in relation to concentration of VC administered
by ingestion for 52 (or 59) weeks.
Animals with fore-
stomach Paand Ac, %
Experiments Concentration, mg/kg M F Total
BT 11 50.00 5.0 - 2.5
16.65 - 2.5 1.2
3.33 - - -
BT 27 1.0 1.3 2.7 2.0
0.3 2.7 - 1.3
0.03 - 1.3 0.7
Controls 0 - 1.7 0.9
BT 11, BT 27
Table 64. Incidence
Table 63. Incidence of mammary MT in female Sprague-
Dawley rats in relation to concentration ofVC administered
by ingestion for 52 (or 59) weeks.
Concentration Animals with
Experiment mg/kg mammary MT, %
BT 11 50.00 10.0
16.65 15.0
3.33 5.0
BT 27 1.0 16.0
0.3 5.5
0.03 18.7
Controls
BT 11 0 10.0
BT 27 0 9.3
sure (so as to define homogeneous exposed groups),
and collect all possible available data on pathology,
we shall have an opportunity, unique at present, to
compare animaland humandata, bothin qualitative
and quantitative terms, and to help find a possible
key for extrapolating from animals to humans.
The Cost
With the presentation made in Paris last Novem-
ber (2) and with today's report, ten years of work
on our VC experimental project seem to be nearly
concluded. After having presented the results, we
also wish to present the data of the cost of the
project, which cannot be expressed only in financial
terms.
The cost of the BT project of long-term carcino-
genicity bioassays on vinyl chloride includes the
cost of (1) the planning and setting-up of experi-
mental apparatus, including inhalation facilities, of
of LAS and Zymbal gland CA in Sprague-Dawley rats in relation to schedule of treatment with VC
administered by inhalation.
Animals with tumors, %
LAS Zymbal gl.ca
Experiment VC concentration, ppm Schedulea M F Total M F Total
BT 1 10,000 I 10.0 13.3 11.7 33.3 20.0 26.7
BT 3 10,000 II - - - 17.8 13.3 15.5
BT 10 10,000 III 1.7 - 0.8 13.5 1.7 7.6
IV 1.7 - 0.8 8.5 6.7 7.6
V - 1.7 0.8 3.3 10.2 6.7
BT 1 6,000 I 10.3 33.3 22.0 10.3 13.3 11.9
BT3 6,000 II - 3.3 1.7 20.0 10.0 15.0
BT 10 6,000 III - - - 10.0 5.0 7.5
IV 3.4 1.7 2.5 8.5 - 4.2
V - 1.7 0.8 10.0 5.0 7.5
aSchedules: ()4hr/day, 5days/wk, 52weeks; (II) 4hr/day, 5days/wk, 17weeks; (III) 4hr/day, 5days/wk, 5weeks; (IV) 1 hr/day, 4
days/wk, 25 weeks; (V) 4 hr/day, 1 day/wk; 25 weeks.
Environmental Health Perspectives 26Table 65. Incidence of LAS in relation to species (male Sprague-Dawley Rats, Wistar rats, Swiss mice and golden hamsters),
treated with VC administered by inhalation.
Concentration, Animals with LAS, %
Experiments ppm Sprague-Dawley rats Wistar rats Swiss mice Golden hamsters
BT1, BT7, BT4, BT8 10,000 10.0 29.6 3.8 -
6,000 10.3 11.5 6.7 3.3
2,500 20.0 12.0 20.7 -
500 - 10.0 20.0 6.7
250 3.4 3.7 30.0 -
50 - - 3.3 -
0 -
Table 66. Incidence of Zymbal gland CA in relation to strain
(male Sprague-Dawley and Wistar rats) treated with VC
administered by inhalation.
Animals with
Zymbal gland CA, %
Concentration, Sprague-
Experiments ppm Dawley rats Wistar rats
BT1, BT7 10,000 33.3 7.4
6,000 10.3 7.7
2,500 3.3 -
500 10.0 -
250 - -
50 _ _
0 _ _
a type uncommon in 1971, and the working out of a
protocol for long-term bioassays; (2) the study of
nearly 7000 animals up to the point oftheir natural
death, equivalent to more than 3,000,000 rodent
days; (3) ten years ofwork; (4) the routine exami-
nation of some 200,000 histological slides; (5) a
financial commitment equivalent to more than
$2,000,000 U.S. at present prices (the average cost
of a rat throughout the world in this type of
experiment is $300 U.S.); (6) the availability ofthe
same team of scientists throughout the entire 10
years of the project, a prerequisite which may be
difficult or even impossible to ensure in many
countries at the present time; (7) the highly moti-
vated commitment of those scientists to a type of
work which is long-lasting, onerous and often
tedious; (8) the effort involved in maintaining the
Table 67. Incidence of LAS in relation to age (newborn and adult) Sprague-Dawley rats treated with VC administered by
inhalation 4 hr/day, 5 days/week, 52 weeks.
Animals with LAS, %
Newborn rats 11 week old rats
Experiment Concentration, ppm M F Total M F Total
BT 10, BT 14 10,000 25.0 45.0 34.1 1.7 - 0.8
6,000 27.8 50.0 40.5 - --
Table 68. Tumors presently correlated to VC exposure, by experiments on rodents.
Angio- Seba- Other
sarcomas ceous cuta- Foresto-
and an- cuta- neous mach pa-
Angio- Tumors Tumors Lympho- giomas Nephro- neous epith- Main- pillomas
sarcomas of of mas and Hepa- of other blasto- carci- elial mary car- and acan- Mela-
Species of liver brain lung leukemias tomas sites mas nomas tumors cinomas thomas nomas
Rat + + + + + + (+) + +
Mouse + + + (+) + (+)
Hamster + (+) (+) (+) + (+
27 October 1981Table 69. Total cancer-bearing animals significantly in excess
by Fisher exact probability test (p 0.05).
Dose level at which total cancer
Sex bearing animals in excess
Male 30,000
10,000
6,000
2,500
500
250
200
50 ppm
50 mg/kg
Female 30,000
10,000
6,000
2,500
500
200
150
50 ppm
50 mg/kg
Table 70. Tumors significantly in excess by Fisher exact
probability test (p
- 0.05).
Doses at which tumors
Tumor type Sex in excess
Zymbal gland carcinoma M 30,000; 10,000 ppm
F 30,000; 10,000 ppm
Liver angiosarcoma M 30,000; 2500; 200 ppm
50 mg/kg
F 30,000; 6000; 2500; 500
200; 150; 50 ppm
50; 16.65 mg/kg
Nephroblastoma M 2500; 200; 150; 100 ppm
F 500; 250 ppm
Neuroblastoma F 10,000 ppm
Mammary gland F 150; 50; 25; 10; 5 ppm
adenocarcinoma
Forestomach papilloma M 30,000 ppm
F 30,000 ppm
Table 71. Onset of tumors considered VC-correlated at the
lowest doses.
Dose Tumors
25 ppm Over 120 animals, 5 liver angiosarcomas,
4 Zymbal gland carcinomas and 1
nephroblastoma
10 ppm Over 120 animals, 1 liver angiosarcoma,
2 extrahepatic angiosarcomas, and 2 Zymbal
gland carcinomas
1 mg/kg Over 150 animals, 3 liver angiosarcomas,
1 extrahepatic angiosarcoma, 1 hepatoma,
and 5 Zymbal gland carcinomas
0.3 mg/kg Over 150 animals, 1 liver angiosarcoma
and 1 hepatoma
28
Table 72. History ofvinyl chloride carcinogenicity studies.
Date
1961 VC was found to produce liver enlargement
and microscopic hepatic degenerative
changes (5)
1970 Zymbal gland carcinomas were reported in
rats exposed to 30,000 ppm of VC, by
inhalation (6)
1970 An increase inatypiasinrespiratory cellswas
observed among workers heavily exposed to
VC (7)
July 1971 A vast project oflong-term carcinogenicity
bioassays on VC was started in Bentivoglio,
near Bologna, Italy (BT project)
August 1972 Zymbal gland carcinomas, nephroblastomas
and liver angiosarcomas were observed in
rats exposed to VC by inhalation (Maltoni,
BT project)
April 1973 The first data ofthe BTproject were released
to the scientific community: the oncogenic
effect was observed up to 250 ppm (4)
1973 Splenomegalic liver disease was found among
poly(vinyl chloride) production workers (8)
December 1973 For the first time a case ofliverangiosarcoma
in a poly(vinyl chloride) production worker
was correlated to VC exposure (9)
February 1974 On the basis ofthe BTproject data indicating
a carcinogenic effect at 250 ppm, OSHA
proposed a TLV of 50 ppm
February 1974 The BT project data showed that VC is a
multipotential carcinogen, producing a
variety oftumors, in different animal species
1974 The BT project data indicated a carcinogenic
effect at 50 ppm (10); OSHA proposed new
stricter rules
1974 Early epidemiological observations (parallel-
ing the experimental information) indicated
an increase in tumors other than liver angio-
sarcomas (ofbrain, lung, liver, hemolympho-
reticular tissues) among workers of VC-PVC
industries (11)
1974-75 BT project data showed that VC had car-
cinogenic effects in rats also when given by
ingestion (12)
1976 In rats ofthe BT project exposed to VC by
inhalation, angiosarcomas were observed
down to the level of25 ppm, and Zymbal
gland carcinomas down to the level of 10 ppm
(13)
consistency of the methodology, which has as its
reverse side the limits placed on the exercise of
imagination-the most positive element in scientific
life; (9) the effort involved in establishing and
preservingobjectivity andbalance intheevaluation
and interpretation of data; (10) and finally, the
strength required to withstand the sense ofloneli-
nessarisingfromthelackofco-operationofmanyof
those bodies which should properly be concerned
with the progress of science in this field, not
excluding part of the scientific community whose
Environmental Health PerspectivesTable 73. Comparative effects of three related compounds-vinyl chloride (VC), vinylidene chloride (VDC) and ethylene
dichloride (EDC) on the same animal systems.
Angio- Tumors of Seba- Fore-
sarcomas the kidney ceous Other stomach
and an- cuta- cuta- papillo-
Angiosar- Tumors Tumors giomas Nephro- Adeno- neous neous Mam- mas and
Com- comas of of the ofthe Hepa- of other blasto- carci- carci- epithelial mary car- acan-
pound Species liver brain lung tomas sites mas nomas nomas tumors cinomas thomas
Rat
(Sprague- + + + + + + (+) + +
Dawley)
VC Mouse
(Swiss) + + + (+) + (+
Rat
(Sprague-
Dawley)
VDC Mouse +
(Swiss)
Rat
(Sprague-
Dawley)
EDC
Mouse
(Swiss)
indifference sometimes degenerates into frank hos-
tility.
The high costs probably represent the reason
why, in the field ofexperimental and environmental
carcinogenesis, words overlap facts, opinions over-
lap data, and meetings and commissions reports
submerge good laboratory work.
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